India, June 22 -- Monday, AbbVie Inc. (ABBV) announced an agreement to acquire Apogee Therapeutics (APGE) for $135.11 per share in cash, valuing the latter at approximately $10.9 billion.
Under the agreement, the company will acquire Apogee's diverse pipeline of multiple clinical-stage candidates in development across inflammatory and immunological diseases, including atopic dermatitis and asthma.
The transaction is expected to strengthen AbbVie's ability to deliver innovative medicines to patients who need better options, advance Apogee's pipeline of highly differentiated clinical-stage assets, and transform the standard of care in inflammatory diseases.
Moreover, the acquisition could create long-term shareholder value with peak sales ...